Bionano Genomics, Inc. (BNGO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cue Biopharma, Inc.

Bionano Genomics, Inc.

Immunome, Inc.

NGM Biopharmaceuticals, Inc.

Sangamo Therapeutics, Inc.

Armata Pharmaceuticals, Inc.

Aadi Bioscience, Inc.

Cyteir Therapeutics, Inc.

Anixa Biosciences, Inc.

IO Biotech, Inc.

Omega Therapeutics, Inc.

Why is Bionano Genomics, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

With a growth in Net Profit of 167.67%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 5 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD -19.31 MM
NET PROFIT(HY) Higher at USD -15.34 MM
ROCE(HY) Highest at -73.78%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -65.23%, its profits have risen by 65.6%

Majority shareholders : FIIs

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 20.78% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -65.23% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bionano Genomics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bionano Genomics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Bionano Genomics, Inc.

-65.23%

-1.20

81.61%

S&P 500

20.78%

1.56

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

27.38%

EBIT Growth (5y)

1.93%

EBIT to Interest (avg)

-68.10

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.41

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.92%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.29

EV to EBIT

0.17

EV to EBITDA

0.24

EV to Capital Employed

-0.22

EV to Sales

-0.20

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-67.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -19.31 MM

NET PROFIT(HY)

Higher at USD -15.34 MM

ROCE(HY)

Highest at -73.78%

RAW MATERIAL COST(Y)

Fallen by -7.03% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.05 times

DEBTORS TURNOVER RATIO(HY)

Highest at 7.68 times

-2What is not working for the Company

INTEREST(HY)

At USD 0.14 MM has Grown at 28.57%

Here's what is working for Bionano Genomics, Inc.

Operating Cash Flow

Highest at USD -19.31 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -15.34 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 2.05 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 7.68 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -7.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Bionano Genomics, Inc.

Interest

At USD 0.14 MM has Grown at 28.57%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)